CN101991792B - Traditional Chinese medicinal composition for treating gout and preparation method thereof - Google Patents
Traditional Chinese medicinal composition for treating gout and preparation method thereof Download PDFInfo
- Publication number
- CN101991792B CN101991792B CN 200910163143 CN200910163143A CN101991792B CN 101991792 B CN101991792 B CN 101991792B CN 200910163143 CN200910163143 CN 200910163143 CN 200910163143 A CN200910163143 A CN 200910163143A CN 101991792 B CN101991792 B CN 101991792B
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- weight
- group
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to the field of traditional Chinese medicines and discloses a traditional Chinese medicinal composition for treating gout, which is preferably prepared from the following raw materials in parts by weight: 240-340 parts of kudzu vine root, 380-480 parts of red-rooted salvia root, 520-620 parts of Japanese Honeysuckle Stem, 420-520 parts of semen coicis and 380-480 parts of plantain seed. The invention further provides a preparation method of the traditional Chinese medicinal composition. The traditional Chinese medicinal composition has the advantages of obvious curative effect on treating the gout, simple formulation and small side effect. The preparation method has the advantage of high extraction rate, is simple to operate and is suitable for industrial production.
Description
Technical field
The present invention relates to tcm field, be specifically related to a kind of Chinese medicine composition for the treatment of gout.
Background technology
Gout be purine metabolic disturbance and (or) urate excretion reduces one group of disease causing, acute arthritis, tophus with hyperuricemia, outbreak repeatedly form, joint deformity can appear in severe patient, gouty nephropathy is clinical characters, purine metabolism obstacle in the morbidity of the clear and definite gout of modern medicine and the body and make that uric acid concentration raises directly related in the blood.
In recent years, raising along with people's living standard, the change of dietary structure, the sickness rate of gout has the trend that increases year by year, the domestic different regions of research report gout prevalence difference, be about 0.0352%-1.33%, the hyperuricemia prevalence is up to 2.44%-13.3%, and the prevalence of gout is 3.1% in the hyperuricemia.The ill age occurred frequently is in 45-65 year.Male's gout prevalence is about 2-3 times of women's prevalence, and male's morbidity is higher than the women before 60 years old, after women's morbidity is common in menopause.Gout is found in each age group, but evident difference is arranged between age groups, and primary gout is more common in middle age, accounts for more than 90%; In child and old gout, secondary gout sickness rate higher [4].The generation of gout is often with multiple disease, and as obesity, hyperlipidemia, hypertension, coronary heart disease, diabetes etc., serious harm patient's physical and mental health and life security thereof cause heavy disease burden for patient family and society.
Gout is chronic disease, and it is primary disease one big characteristics that acute attack stage and catabasis change occur.Modern medicine does not still have the specially good effect prophylactico-therapeutic measures to this disease at present, and Drug therapy mainly is to carry out symptomatic treatment and uric acid reducing treatment according to the state of an illness.Acute stage, selected anti-inflammation and analgesic drugs such as colchicine, nonsteroidal anti inflammatory medicine (indometacin, piroxicam etc.), glucocorticoid, and with anti-inflammatory analgetic, relief of symptoms is purpose rapidly.Outbreak intermission and chronic phase; select to reduce the medicine of blood uric acid; comprise uric acid synthetic inhibitor such as allopurinol etc. and promote urate excretion medicine such as probenecid; benzbromarone etc.; purpose is by uric acid concentration in the control blood; the acute attack of prevention gouty arthritis prevents that lithangiuria from generating, the protection renal function.But the western medicine gout exists the big grade of side effect obviously not enough, and simultaneously, gout has the characteristics of outbreak repeatedly again, and the patient is difficult to accept to take for a long time Western medicine.
At present, Chinese medicine gout research report is increasing, is accepted by vast patient with gout because its side effect is little.But make a general survey of the Recent study overview, remain in many problems, the person is many as the decoction plus-minus, and the fixed dosage form person is few etc.Particularly the animal experiment study to aspects such as mechanism of drug action, links does not appear in the newspapers as yet.In view of this, utilize modern science and technology equipment and method, inquire into the gout etiology and pathogenesis, the screening verification active drug is developed Chinese medicine preparation with strong points, that curative effect is sure, dosage form is easy, is the current key issue that needs to be resolved hurrily.
Summary of the invention
The technical issues that need to address of the present invention just are to overcome the defective that the western medicine effect is undesirable and side effect is big of existing treatment gout, and a kind of Chinese medicine composition that gout is with strong points, evident in efficacy and side effect is little for the treatment of is provided.
In order to realize the foregoing invention purpose, the present invention adopts following technical scheme:
A kind of Chinese medicine composition for the treatment of gout, its raw material comprises Radix Puerariae, Radix Salviae Miltiorrhizae, Caulis Lonicerae, Semen Coicis and Semen Plantaginis.
Chinese medicine composition of the present invention, its raw material preferably includes: Radix Puerariae 240～340 weight portions, Radix Salviae Miltiorrhizae 380～480 weight portions, Caulis Lonicerae 520～620 weight portions, Semen Coicis 420～520 weight portions, Semen Plantaginis 380～480 weight portions.
Further preferably, the raw material of Chinese medicine composition of the present invention comprises: Radix Puerariae 286 weight portions, Radix Salviae Miltiorrhizae 429 weight portions, Caulis Lonicerae 571 weight portions, Semen Coicis 476 weight portions, Semen Plantaginis 429 weight portions.
Chinese medicine composition of the present invention directly or indirectly adds acceptable accessories through conventional processing and makes granule, pill, powder, tablet, capsule, oral liquid.The preferred dosage form of Chinese medicine composition of the present invention is granule.
Preferably, described adjuvant comprises dextrin and steviosin.Described steviosin preferred weight accounts for 5 ‰ of Radix Puerariae, Radix Salviae Miltiorrhizae, Caulis Lonicerae, Semen Coicis and Semen Plantaginis total amount, and described dextrin preferred weight is 1: 1.5～3 with the total amount ratio of Radix Puerariae, Radix Salviae Miltiorrhizae, Caulis Lonicerae, Semen Coicis, Semen Plantaginis.
The invention also discloses a kind of preparation method of described Chinese medicine composition, may further comprise the steps:
Step a: Radix Salviae Miltiorrhizae extracts secondary with alcohol heating reflux, and merge extractive liquid, filters, and gets filtrate and is concentrated into 60 ℃～75 ℃ to survey relative densities be 1.20～1.22 clear paste, and is standby;
Step b: step a is filtered the gained medicinal residues decoct with water twice, merging filtrate, being concentrated into 60 ℃～75 ℃, to survey relative densities be 1.20～1.22 clear paste, standby;
Step c: Radix Puerariae, Caulis Lonicerae, Semen Coicis, Semen Plantaginis are added alcohol heating reflux extract secondary, merge extractive liquid, filters, and being concentrated into 60 ℃～75 ℃, to survey relative densities be 1.20～1.22 clear paste, standby;
Steps d: each step gained clear paste is merged, be Chinese medicine composition of the present invention.
Wherein to be preferably volume ratio be 80% ethanol to the described ethanol of step a, the 8-12 that its consumption that refluxes for the first time is preferably Radix Salviae Miltiorrhizae weight doubly, the 6-10 that its consumption that refluxes for the second time is preferably Radix Salviae Miltiorrhizae weight is doubly.
Twice decocting time of step b preferably was respectively 2 hours, 1 hour.
It is 50% ethanol that the described ethanol of step c is preferably volume ratio, its consumption that refluxes for the first time is preferably Radix Puerariae, Caulis Lonicerae, Semen Coicis, Semen Plantaginis gross weight 8 times, and its consumption that refluxes for the second time is preferably Radix Puerariae, Caulis Lonicerae, Semen Coicis, Semen Plantaginis gross weight 6 times.
Chinese medicine composition of the present invention is applicable to the pyretic arthralgia in the rheumatic arthralgia, and with the joint joint stuffiness, red and swollen heat pain is primary symptom, is that rheumatism is invaded the flesh natural fibre line of meat, flows in the joint, due to the strongly fragrant heat-transformation of a specified duration.Damp and hot retardance, grain is obstructed, and articular instability is so be seen in card.We are monarch with Semen Coicis, Radix Puerariae two medicines, sweet light being slightly cold of Semen Coicis, sweet can emergency, light can eliminating dampness by diuresis, cold can heat clearing away, be usually used in the rheumatism lingering arthralgia, strongly fragrant and heat-transformation person, according to " herbal classic " record, this product " main muscular contracture contracture, unable to flex and stretch the extremities, rheumatism numbness "; Radix Puerariae, " herbal classic ": " main quenching one's thirst, high fever of the body, vomiting, all numbness plays cloudy gas, separates all poison ", two medicines are harmonious, and play the merit of clearing heat and expelling damp detoxifcation altogether.Caulis Lonicerae is the stem and leaf of Radix Ophiopogonis, has another name called Caulis Lonicerae, in heat-clearing and toxic substances removing, is good at the heat of dispeling the wind, the meridian dredging and stopping numbness pain; Radix Salviae Miltiorrhizae, " herbal classic " put down in writing, the Radix Salviae Miltiorrhizae removing heat from blood and promoting blood circulation, " Japan hanako materia medica " record: Radix Salviae Miltiorrhizae energy tonneau GUAN-pulse, control arthralgia, extremity are unsuccessful, and two medicines are ministerial drug altogether, a principal drug assistance damp eliminating thermal detoxification, a principal drug assistance the meridian dredging pain relieving, the monarch and his subjects get mutually, restrain the merit of fainting altogether.Semen Plantaginis is sweet cold, goes into Liver and kidney two warps, can ooze the damp and hot of relieving rigidity of muscles and joints, makes it to go out from lower orifices, can remove arthralgia chiefly caused by damp pathogen, pain relieving, dredging water passages and diuresis is adjuvant.Above-mentioned five medicines are harmonious, and play clearing away heat-damp and promoting diuresis altogether, and the merit of removing obstruction in the collateral to relieve pain makes diarrhea due to damp-heat and wind removes, and through ruton and the numbness solution, all cards are then from removing.
Of the present inventionization sanction ancient prescription, a kind of new Chinese medicine for the treatment of gout of combination, it is little to write out a prescription, and has treating both the principal and secondary aspects of a disease, evident in efficacy, advantages such as side effect is little, taking convenience, price economy.Its production technology advanced person is beneficial to suitability for industrialized production.
The specific embodiment
Below in conjunction with embodiment, further set forth the present invention:
Embodiment 1:
Step a: the preparation method of Radix Salviae Miltiorrhizae extract: Radix Salviae Miltiorrhizae 480g adds 4800 milliliters, 3840 milliliter 80% alcohol heating reflux respectively and extracts secondary, 2 hours time, 1 hour, merge extractive liquid,, filter, be concentrated into relative density and be the about 234g of clear paste of 1.20～1.22 (60～75 ℃), standby;
Step b: medicinal residues add 3840 milliliters in water, 2880 milliliters respectively, decoct 2 hours, 1 hour, and merging filtrate is concentrated into relative density and is the about 328g of clear paste of 1.20～1.22 (60～75 ℃), and is standby;
Step c: the preparation method of Radix Puerariae, Caulis Lonicerae, Semen Coicis, Semen Plantaginis extract: Radix Puerariae 340g, Caulis Lonicerae 620g, Semen Coicis 520g, Semen Plantaginis 480g, add 15680 milliliters of 50% ethanol, 11760 milliliters of heating and refluxing extraction secondaries respectively, 2 hours time, 1 hour, merge extractive liquid,, filter, be concentrated into relative density and be the about 502g of clear paste of 1.20～1.22 (60～75 ℃), standby;
Steps d: above-mentioned clear paste is merged, namely get Chinese medicine composition of the present invention.
Embodiment 2:
Step a: the preparation method of Radix Salviae Miltiorrhizae extract: Radix Salviae Miltiorrhizae 380g adds 3800 milliliters, 3040 milliliter 80% alcohol heating reflux respectively and extracts secondary, 2 hours time, 1 hour, merge extractive liquid,, filter, be concentrated into relative density and be the about 191g of clear paste of 1.20～1.22 (60～75 ℃), standby;
Step b: medicinal residues add 3040 milliliters in water, 2280 milliliters respectively, decoct 2 hours, 1 hour, and merging filtrate is concentrated into relative density and is the about 268g of clear paste of 1.20～1.22 (60～75 ℃), and is standby;
Step c: the preparation method of Radix Puerariae, Caulis Lonicerae, Semen Coicis, Semen Plantaginis extract: Radix Puerariae 240g, Caulis Lonicerae 520g, Semen Coicis 420g, Semen Plantaginis 380g, add 12480 milliliters of 50% ethanol, 9360 milliliters respectively, the heating and refluxing extraction secondary, 2 hours time, 1 hour, merge extractive liquid,, filter, be concentrated into relative density and be the about 415g of clear paste of 1.20～1.22 (60～75 ℃), standby;
Steps d: above-mentioned clear paste is merged, make granule with dextrin 589g, steviosin 5g, fill namely gets the granule of Chinese medicine composition of the present invention.
Embodiment 3:
Step a: the preparation method of Radix Salviae Miltiorrhizae extract: Radix Salviae Miltiorrhizae 429g adds 4290 milliliters, 3432 milliliter 80% alcohol heating reflux respectively and extracts secondary, 2 hours time, 1 hour, merge extractive liquid,, filter, be concentrated into relative density and be the about 212g of clear paste of 1.20～1.22 (60～75 ℃), standby;
Step b: medicinal residues add 3432 milliliters in water, 2574 milliliters respectively, decoct 2 hours, 1 hour, and merging filtrate is concentrated into relative density and is the about 294g of clear paste of 1.20～1.22 (60～75 ℃), and is standby;
Step c: the preparation method of Radix Puerariae, Caulis Lonicerae, Semen Coicis, Semen Plantaginis extract: Radix Puerariae 286g, Caulis Lonicerae 571g, Semen Coicis 476g, Semen Plantaginis 429g, add 14096 milliliters of 50% ethanol, 10572 milliliters respectively, the heating and refluxing extraction secondary, 2 hours time, 1 hour, merge extractive liquid,, filter, be concentrated into relative density and be the about 451g of clear paste of 1.20～1.22 (60～75 ℃), standby;
Steps d: above-mentioned clear paste merges, and makes granule with the about 550g of dextrin, steviosin 5g, and fill namely gets the granule of Chinese medicine composition of the present invention.
Embodiment 4: Chinese medicine composition of the present invention causes the influence of the pain mice threshold of pain to hot plate
Get female KM mice, body weight (20 ± 2) g, be placed on (55.0 ± 0.5) ℃ intelligent hot-plate instrument, choose the mice that licks metapedes in the 5s-30s and be shown qualified mice, get 50 of the qualified mices of preliminary election, by body weight it is divided into the heavy dose of group of granule of normal saline matched group (calling the ordinary water group in the following text), positive drug (the TONGFENGDING capsule is by Zhonghui Pharmacy Co., Ltd., Chengdu) matched group, embodiment 2 preparations, middle dosage group, small dose group, 10 every group at random.Before the administration, measure and respectively to organize the mice hot plate and lick the sufficient time (being pain threshold), every mice surveys twice, get its meansigma methods as medicine before pain threshold.Each organizes mice by the gastric infusion of dosage shown in the table 1, wherein positive drug is worked as in 10 times of people's clinical application amount, the large, medium and small dosage of gout granules is equivalent to 20 times, 10 times, 5 times of people's clinical application amount respectively, the ordinary water group is irritated stomach equivalent normal saline, every day 1 time, continuous irrigation stomach 7 days, each is organized mice diet drinking-water and is not limit.Measure the pain threshold 1 time of respectively organizing mice respectively at 15min, 30min after the last administration, 60min, 90min, the threshold of pain surpasses 60s in 60s.
The results are shown in Table 1.
The granule of table 1 embodiment 2 preparation to hot plate method cause pain mice pain threshold influence (x ± s, n=10)
| Group | Dosage/gkg -1 | Pain threshold/s before the medicine | 15min/s behind the medicine | 30min/s behind the medicine | 60min/s behind the medicine | 90 min/s behind the medicine |
| Ordinary water | Equal-volume | 18.329± 5.064 | 17.057± 5.388 | 14.516± 4.401 | 13.512± 4.928 | 12.157± 4.524 |
| TONGFENGDING | 0.8 | 17.273± 3.322 | 17.215± 5.967 | 15.356± 3.618 | 15.042± 2.905 | 16.141± 7.582 |
| Heavy dose of | 15.40 | 18.478± 4.826 | 19.874± 7.000 | 16.362± 4.724 | 15.227± 4.203 | 16.246± 3.089 * |
| Middle dosage | 7.70 | 17.514± 4.287 | 18.184± 4.693 | 18.752± 6.289 | 16.807± 5.314 | 16.243± 4.035 * |
| Low dose of | 3.85 | 17.712± 4.408 | 18.865± 5.641 | 16.073± 5.460 | 14.861± 4.858 | 13.459± 4.192 |
Annotate: compare with the ordinary water group,
*P＜0.05.
The result shows that the big or middle dosage of granule of embodiment 2 preparations can significantly improve mice hot plate pain threshold, and analgesic activity is preferably arranged.With reference to above-mentioned experimental technique the Chinese medicine composition of embodiment 1, embodiment 3 preparations is tested, proved all have similar analgesic effect.
Embodiment 5: Chinese medicine composition Dichlorodiphenyl Acetate of the present invention causes the influence of pain mouse writhing reaction
Get 50 of KM mices, male and female half and half, body weight (20 ± 2) g, with its random packet administration (with embodiment 4), the ordinary water group is irritated stomach equivalent ordinary water, irritates stomach every day 1 time by body weight, and continuous 7 days, each was organized mice diet drinking-water and is not limit.Behind last administration 30min, every mouse peritoneal is injected 0.6% acetic acid 0.2mL, and that records that mice in time (namely turn round body incubation period) of the 1st writhing response and the 15min appears in each Mus turns round the body number of times.
The results are shown in Table 2.
The granule Dichlorodiphenyl Acetate of table 2 embodiment 3 preparation causes the influence (x ± s) of pain mouse writhing reaction
| Group | Dosage/gkg -1 | The example number | Turn round body incubation period/s | Turn round body/time | The analgesia rate |
| Ordinary water | Equal-volume | 10 | 248.6±71.146 | 34.5±11.048 | - |
| TONGFENGDING | 0.8 | 10 | 351.8±153.803 | 17.6±8.249 ** | 48.99％ |
| Heavy dose of | 15.40 | 10 | 303.7±71.413 | 15.3±7.573 *** | 55.65％ |
| Middle dosage | 7.70 | 10 | 428.2±125.063 ** | 11.5±5.255 *** | 66.67％ |
| Low dose of | 3.85 | 10 | 337.2±104.957 * | 20.2±6.529 ** | 41.45％ |
Annotate: compare with the ordinary water group,
*P＜0.05,
*P＜0.01,
* *P＜0.001.
Turn round body analgesia rate=(the ordinary water group is on average turned round body number of times-administration group and on average turned round the body number of times)/ordinary water group and on average turn round body number of times * 100%
The result shows, the granule of embodiment 3 preparations can the significant prolongation mouse writhing incubation period, reduce decimal and turn round the body number of times, mice acetic acid is caused pain analgesic activity preferably.With reference to above-mentioned experimental program the Chinese medicine composition of embodiment 1, embodiment 2 preparations is tested, prove all have significant prolongation mouse writhing incubation period, reduce decimal and turn round the body number of times, mice acetic acid is caused analgesic activity preferably bitterly.
Embodiment 6: Chinese medicine composition xylol of the present invention causes the influence of mice auricle swelling
Get 50 of KM mices, male, body weight (20 ± 2) g is divided into group administration (with embodiment 4) by body weight at random with it, and the ordinary water group is irritated stomach equivalent ordinary water, irritates stomach every day 1 time, and continuous 7 days, each was organized mice diet drinking-water and does not limit.Behind last gastric infusion or the ordinary water 1h, 0.02mL/ caused by dimethylbenzene xylene inflammation of two sided coatings before and after every group of mouse right ear, the execution mice is cut ears and lays round auricle at same position respectively with 9mm (diameter) card punch behind the 4h, weighs, to calculate the swelling rate.
The results are shown in Table 3.
The Chinese medicine composition xylol of table 3 embodiment 1 preparation causes the influence of mice auricle swelling
| Group | Dosage/gkg -1 | Number of animals/only | The ear swelling rate (
 |
Suppression ratio |
| Ordinary water | Equal-volume | 10 | 0.657±0.295 | - |
| TONGFENGDING | 0.8 | 10 | 0.548±0.317 | 16.59％ |
| Heavy dose of | 15.40 | 10 | 0.304±0.150 **Δ | 53.73％ |
| Middle dosage | 7.70 | 10 | 0.492±0.256 | 25.11％ |
| Low dose of | 3.85 | 10 | 0.461±0.255 | 29.83％ |
Annotate: compare with the ordinary water group,
*P＜0.01; Compare with the TONGFENGDING group
ΔP＜0.05.
The swelling rate=(auris dextra sheet weight-left auricle is heavy)/left auricle is heavy
Inhibitory rate of intumesce=(the average ear swelling rate of the ordinary water group-average ear swelling rate of administration the group)/average ear swelling rate of ordinary water group * 100%
The result shows that the heavy dose of xylol of the Chinese medicine composition of embodiment 1 preparation causes mice auricle swelling and has significant inhibitory effect, and acute inflammation is had good inhibitory effect.With reference to above-mentioned experimental program the Chinese medicine composition of embodiment 2, embodiment 3 preparations is tested, proving has good inhibitory effect to acute inflammation.
Embodiment 7: Chinese medicine composition Dichlorodiphenyl Acetate of the present invention causes the influence that the mice capillary permeability increases
Get 50 of KM mices, male and female half and half, body weight (20 ± 2) g, with its random packet, administration (with embodiment 4), the ordinary water group is irritated stomach equivalent ordinary water, irritates stomach every day 1 time by body weight, and continuous 7 days, each was organized mice diet drinking-water and is not limit.1h behind the last filling stomach, each organizes mouse tail vein injection 0.5% azovan blue 0.1mL10g
-1(with weighing machine), lumbar injection 0.6% acetum 0.1mL10g immediately
-1, take off cervical vertebra behind the 20min and put to death mice, cut off skin of abdomen, divide with the 6mL normal saline and wash the abdominal cavity for several times, collect cleaning mixture, add normal saline after the merging to 10mL, with the centrifugal 15min of 3000rpm, get supernatant and measure absorbance in spectrophotometer 590nm place.
The results are shown in Table 4.
The granule Dichlorodiphenyl Acetate of table 4 embodiment 2 preparations causes the influence that the mouse peritoneal capillary permeability increases
| Group | Dosage/gkg -1 | Number of animals/only | Absorbance (
|
Suppression ratio |
| Ordinary water | Equal-volume | 10 | 0.242±0.0532 | - |
| TONGFENGDING | 0.8 | 10 | 0.168±0.0706 * | 30.6％ |
| Heavy dose of | 15.40 | 10 | 0.148±0.0758 ** | 38.8％ |
| Middle dosage | 7.70 | 10 | 0.143±0.0609 ** | 40.9％ |
| Low dose of | 3.85 | 10 | 0.147±0.0597 ** | 39.3％ |
Annotate: compare with the ordinary water group,
*P＜0.05,
*P＜0.01.
Suppression ratio=(ordinary water group mean light absorbency value-administration group mean light absorbency value)/ordinary water group mean light absorbency value * 100%
The result shows that the large, medium and small dosage group of gout granules Mus peritoneal exudate absorbance and ordinary water group compare, and difference has highly significant meaning (P＜0.01).
The result shows, the granule of embodiment 2 preparations can significantly reduce acetic acid and cause the mouse peritoneal capillary permeability and increase, and reduces its inflammation and oozes out.With reference to above-mentioned experimental program the Chinese medicine composition of embodiment 1, embodiment 3 preparations is tested, proved that can significantly reduce acetic acid causes the mouse peritoneal capillary permeability and increase, and reduces its inflammation and oozes out.
Embodiment 8: Chinese medicine composition on Carrageenan of the present invention causes the influence of rat paw edema
Get 40 of Wistar rats, male, by body weight it is divided into dosage group, gout granules small dose group in the heavy dose of group of gout granules, gout granules of ordinary water group, positive drug (TONGFENGDING capsule) matched group, embodiment 3 preparations, 8 every group at random.Each organizes the rat oral gavage administration, and wherein positive drug is 0.4gkg
-1, being equivalent to 5 times of people's clinical application amount, the gout granules heavy dose is 7.70gkg
-1, middle dosage is 3.85gkg
-1, low dose is 1.93gkg
-1, be equivalent to 10 times, 5 times, 2.5 times of people's clinical application amount respectively; The ordinary water group is irritated stomach equivalent ordinary water.Irritate stomach every day 1 time, continuous 7 days.Each is organized rat diet drinking-water and is not limit.
1h behind last gastric infusion or the ordinary water, every group of rat right hind leg foot plantar subcutaneous injection 1% carrageenin 0.1mL/ only, respectively at before the injection carrageenin, injection 30min, injection 1h, injection 2h, injection 4h, injection 6h measure rat foot girth, to calculate the swelling degree.
The results are shown in Table 5.
The granule on Carrageenan of table 5 embodiment 3 preparation cause the rat paw edema degree influence (x ± s, n=8)
| Group | Swelling 30min | Swelling 1h | Swelling 2h | Swelling 4h | Swelling 6h |
| The ordinary water group | 0.208± 0.0767 | 0.344± 0.1095 | 0.323± 0.0975 | 0.499± 0.1303 | 0.528± 0.1036 |
| TONGFENGDING | 0.172± 0.0947 | 0.218± 0.0966 * | 0.243± 0.0986 | 0.373± 0.0959 * | 0.366± 0.0706 ** |
| Heavy dose of | 0.176± 0.0694 | 0.193± 0.0749 ** | 0.193± 0.0853 * | 0.381± 0.1227 | 0.392± 0.1021 ** |
| Middle dosage | 0.155± 0.0736 | 0.120± 0.0687 *** | 0.114± 0.0888 ** | 0.264± 0.1431 ** | 0.359± 0.1081 ** |
| Low dose of | 0.142± 0.0579 | 0.147± 0.0474 ** | 0.156± 0.0541 ** | 0.310± 0.0456 ** | 0.280± 0.0651 *** |
Annotate: compare with the ordinary water group,
*P＜0.05,
*P＜0.01,
* *P＜0.001; Compare with the TONGFENGDING group,
ΔP＜0.05.
Girth before swelling degree=(girth before injection back girth-injection)/injection
The result shows, rat paw edema has good inhibition effect due to the granule on Carrageenan of embodiment 3 preparations, points out this medicine that antiinflammatory action is preferably arranged.With reference to above-mentioned experimental program the Chinese medicine composition of embodiment 1, embodiment 2 preparations is tested, proved all have antiinflammatory action preferably.
Embodiment 9: Chinese medicine composition of the present invention causes the influence of mice hyperuricemia to yeast extract
Get 60 KM mices, by body weight its Chinese medicine composition that is divided into ordinary water matched group, model group, positive drug (TONGFENGDING capsule) group, embodiment 1 preparation at random is subjected to the heavy dose of group of reagent, is subjected to dosage group in the reagent, is subjected to the reagent small dose group, every group 10, male and female half and half.Except the normal control group, all the other each groups are all with yeast extract 30gkg
-1D
-1Irritate the stomach modeling, the ordinary water matched group is irritated stomach equivalent ordinary water, continuous 7 days.Each treated animal gastric infusion same period, dosage are with embodiment 4, and ordinary water group, model group are irritated stomach equivalent ordinary water, every day 1 time, continuous 7 days.Each treated animal diet drinking-water is not limit.In experiment the 8th day, each was organized the mice broken end and gets blood, separation of serum, the content of uric acid in the mensuration serum.
The results are shown in Table 6.
The Chinese medicine composition of table 6 embodiment 1 preparation is to the influence of mice hyperuricemia serum uric acid content (x ± s)
| Group | Dosage/gkg -1 | Number of animals/only | Serum UA/ μ molL -1 |
| The ordinary water group | Equal-volume | 10 | 147.308±27.612 |
| Model group | Equal-volume | 10 | 210.888±58.367 ** |
| TONGFENGDING | 0.8 | 10 | 174.401±49.961 |
| Heavy dose of | 15.40 | 10 | 161.953±45.239 |
| Middle dosage | 7.70 | 10 | 180.655±61.518 |
| Low dose of | 3.85 | 10 | 186.581±72.546 |
Annotate: compare with the ordinary water group,
*P＜0.01.
The result shows, mice gives yeast extract and irritates the stomach modeling after 7 days, uric acid content significantly increases in the mice serum, formed hyperuricemia, each dosage of Chinese medicine composition of embodiment 1 preparation can suppress the unusual rising by uric acid in the yeast extract induced mice hyperuricemia serum, and the prompting gout granules has reduction trend to the mice hyperuricemia.With reference to above-mentioned experimental program the Chinese medicine composition of embodiment 2, embodiment 3 preparations is tested, proved all have the effect that reduces the mice hyperuricemia.
Embodiment 10: Chinese medicine composition of the present invention is to the influence of hyperuricemia rat
Get 60 male Wistar rats, by body weight its Chinese medicine composition that is divided into ordinary water matched group, model group, positive drug (TONGFENGDING capsule) group, embodiment 1 preparation at random is subjected to the heavy dose of group of reagent, is subjected to dosage group in the reagent, is subjected to the reagent small dose group, 10 every group.Except the ordinary water group, all the other each groups are all with adenine (100mgkg
-1), ethambutol sheet (100mgkg
-1) irritate the stomach modeling, the normal control group is irritated stomach equivalent ordinary water, every day 1 time, continuous 7 days.Each treated animal is pressed the gastric infusion of dosage shown in the table 7 same period, and ordinary water group, model group are irritated stomach equivalent ordinary water, every day 1 time, continuous 7 days.Each is organized rat diet drinking-water and is not limit.In experiment the 8th day, each is organized rat heart and gets blood, and was centrifugal, separation of serum, the content of uric acid in the mensuration serum.
The results are shown in Table 7.
The Chinese medicine composition of table 7 embodiment 1 preparation is to the influence of rat hyperuricemia serum uric acid content (x ± s)
Annotate: compare with the ordinary water group,
*P＜0.05,
*P＜0.01,
* *P＜0.001; Compare with model group,
ΔP＜0.05.
The result shows that the mixed liquor of irritating gastric gland purine and ebutol sheet can cause the rat hyperuricemia model; The Chinese medicine composition heavy dose of embodiment 1 preparation can obviously suppress increasing unusually of uric acid in the hyperuricemia rat model serum, and the Chinese medicine composition of prompting embodiment 1 preparation has therapeutical effect preferably to the rat hyperuricemia.With reference to above-mentioned experimental program the Chinese medicine composition of embodiment 2, embodiment 3 preparations is tested, proving all has therapeutical effect preferably to the rat hyperuricemia.
Embodiment 11: Chinese medicine composition of the present invention causes the influence of ankle swelling in rat to uric acid sodium
Get 50 of Wistar Mus, male, body weight (200 ± 20) g, the labelling of weighing is divided into the ordinary water group at random, and positive drug (TONGFENGDING capsule) group is subjected to the large, medium and small dosage group of reagent, 10 every group.Each administration group rat is pressed table 10 dosage gastric infusion, and the ordinary water group is irritated stomach equal-volume ordinary water, every day 1 time, continuous 7 days.In administration the 5th day, measure every rat right hind leg ankle joint girth, 1h behind the gastric infusion, every rat is all with MSU suspension 0.2mL ankle joint injection modeling.Respectively organize rat swelling limb ankle joint girth respectively at 3h, 24h, 48h, 72h behind the injection MSU with the tape measurement, and observe and respectively organize the variation of rat gait, carry out rank scores according to table 8,72h respectively organizes rat extracting blood, carry out numeration of leukocyte, put to death rat, get and tried the knuckle synovia film and check as pathology, carry out rank scores by table 9.The results are shown in Table 10, table 11, table 12, table 13.
Table 8 rat gait rank scores standard
| Classification | Gait changes | Scoring |
| 0 grade | Normal walking | 0 minute |
| The I level | The slight limping, it is slightly crooked to be tried lower limb | 1 minute |
| The II level | Moderate is walked lamely, and is tried that lower limb can only touch ground and can not be stressed | 2 minutes |
| The III level | Severe is walked lamely, and is tried the crooked built on stilts of lower limb, the tripodia walking | 3 minutes |
Table 9 rat ankle joint Synovial membrane pathological grading standards of grading
| Classification | Pathological change | Scoring |
| 0 grade | The sliding formwork histiocyte is monolayer alignment, the NIP reaction. | 0 minute |
| The I level | Synovial membrane is visible fine hair shape hypertrophy still, and mucinous degeneration is light slightly, and seeing has plasmocyte infiltrating, and muscle does not have necrosis. | 1 minute |
| The II level | Visible kitchen range shape necrosis in the synovial membrane, synovial membrane is fine hair shape hypertrophy, and connective tissue has mucinous degeneration under the fine hair, and muscular fascia has a small amount of necrosis or obviously congested, the visible monokaryon of mucous layer, lymphocytic infiltration. | 2 minutes |
| The III level | The necrosis of synovial layer kitchen range shape comes off, hyperemia, and connective tissue has mucinous degeneration and the necrosis of kitchen range shape under the fine hair, and has a large amount of eosinophilic granulocytes to soak into, visible neutrophil infiltration, skeletal muscle is most of downright bad, minute blood vessel congestion and edema, interstitial edema. | 3 minutes |
The granule of table 10 embodiment 3 preparation causes the leukocytic influence of rat gouty arthritis model (x ± s) to uric acid sodium
| Group | Dosage/gkg -1 | Number of animals/only | Leukocyte/* 10 9 |
| The ordinary water group | Equal-volume | 10 | 27.45±17.652 |
| TONGFENGDING | 0.4 | 10 | 21.33±12.004 |
| Heavy dose of | 7.70 | 10 | 10.39±5.718 * |
| Middle dosage | 3.85 | 10 | 13.26±5.257 * |
| Low dose of | 1.93 | 10 | 10.00±5.017 * |
Annotate: compare with the ordinary water group,
*P＜0.05.
The result shows that the large, medium and small dosage of granule of embodiment 3 preparations all can significantly suppress the leukocytic increase of rat model, points out this medicine various dose that the caused arthritis reaction-leukocyte recruitment of uric acid sodium is all had obvious inhibitory action.
The granule of table 11 embodiment 3 preparation causes influence (n=10, the x ± s) of rat gouty arthritis model ankle swelling to uric acid sodium
| Group | Swelling 3h | Swelling 24h | Swelling 48h | Swelling 72h |
| The ordinary water group | 0.302±0.0639 | 0.276±0.0457 | 0.205±0.0331 | 0.172±0.0308 |
| TONGFENGDING | 0.262±0.0436 | 0.239±0.0520 | 0.166±0.0499 | 0.133±0.0497 |
| Heavy dose of | 0.277±0.0326 | 0.263±0.0443 | 0.178±0.0421 | 0.155±0.0371 |
| Middle dosage | 0.284±0.0444 | 0.235±0.0243 * | 0.165±0.0392 * | 0.147±0.0356 |
| Low dose of | 0.234±0.0464 * | 0.239±0.0541 | 0.200±0.0500 | 0.143±0.0349 |
Annotate: compare with the ordinary water group,
*P＜0.05.
The result shows that embodiment 3 preparation granules have obvious inhibitory action to the rat specificity arthritis swelling due to the injection of uric acid sodium salt.
The granule of table 12 embodiment 3 preparation causes the influence that gouty arthritis rat model gait changes (n=10, x ± s) to uric acid sodium
Annotate: compare with the ordinary water group,
*P＜0.05.
The result shows that the granule of embodiment 3 preparations can alleviate gouty arthritis rat model limping symptom.
The granule of table 13 embodiment 3 preparation causes the influence (x ± s) of gouty arthritis rat knuckle synovia film pathology to uric acid sodium
| Group | Dosage/gkg -1 | Number of animals/only | 0 grade/only | The I level/only | The II level/only | The III level/only |
| The ordinary water group | Equal-volume | 10 | 0 | 0 | 3 | 7 |
| TONGFENGDING | 0.4 | 10 | 0 | 1 | 6 | 3 |
| Heavy dose of | 7.70 | 10 | 0 | 2 | 8 | 0** |
| Middle dosage | 3.85 | 10 | 0 | 1 | 7 | 2* |
| Low dose of | 1.93 | 10 | 0 | 1 | 5 | 4 |
Annotate: compare with the ordinary water group,
*P＜0.05,
*P＜0.01; The pathology photo is attached.
The big or middle dosage of granule of embodiment 3 preparations can significantly improve MSU and cause the pathological change of rat gouty arthritis ankle joint.
With reference to above-mentioned experimental program the Chinese medicine composition of embodiment 1, embodiment 2 preparations is tested, proved all have similar therapeutic effect.
Embodiment 12: Chinese medicine composition of the present invention causes the influence of tame rabbit knee swelling to uric acid sodium
Get 30 healthy male rabbits, be divided into 5 groups at random, every group 6, grouping is with embodiment 4, except the ordinary water group is irritated the stomach equivalent ordinary water every day, all the other each groups are pressed the gastric infusion of dosage shown in the table 15, continuous 7 days, 30min after the administration in the 5th day, each organizes right back knee joint intracavitary administration uric acid sodium (MSU) suspension (100mg/mL) 0.3mL, matched group injection equivalent normal saline, measure knee joint swelling degree with 3h, 12h, 24h, 72h behind the injection MSU, observe the rabbit gait and change, the execution rabbit is got the knee joint synovial membrane and does pathologic finding behind the 72h, gets determination of serum blood uric acid content.Measure with tape respectively at 3h, 24h, 48h, 72h behind the injection MSU and respectively to organize rat swelling limb ankle joint girth, 72h puts to death rat, gets to be tried the knuckle synovia film and check as pathology, carries out rank scores by table 14.
The pathological grading standard of the tame rabbit knee Synovial membrane of table 14
| Classification | The inflammation pathological manifestations | Scoring |
| 0 grade | The sliding formwork histiocyte is monolayer alignment, the NIP performance. | 0 minute |
| The I level | Synovial membrane is visible fine hair shape hypertrophy still, and mucinous degeneration is light slightly, and seeing has plasmocyte infiltrating, and muscle does not have necrosis. | 1 minute |
| The II level | Visible kitchen range shape necrosis in the synovial membrane, synovial membrane is fine hair shape hypertrophy, and connective tissue has mucinous degeneration under the fine hair, and muscular fascia has a small amount of necrosis or obviously congested, the visible monokaryon of mucous layer, lymphocytic infiltration. | 2 minutes |
| The III level | The necrosis of synovial layer kitchen range shape comes off, hyperemia, and connective tissue has mucinous degeneration and the necrosis of kitchen range shape under the fine hair, and has a large amount of eosinophilic granulocytes to soak into, visible neutrophil infiltration, skeletal muscle is most of downright bad, minute blood vessel congestion and edema, interstitial edema. | 3 minutes |
See Table 15, table 16.
The granule of table 15 embodiment 2 preparation is to the influence of model rabbit articular cavity swelling (n=6, x ± s)
| Group | Dosage/gkg -1 | Swelling rate/3h | Swelling rate/12h | Swelling rate/24h | Swelling rate/48h | Swelling rate/72h |
| Ordinary water | Equal-volume | 0.160±0.130 | 0.236±0.173 | 0.197±0.121 | 0.229±0.143 | 0.239±0.185 |
| TONGFENGDING | 0.28 | 0.135±0.078 | 0.187±0.035 | 0.191±0.070 | 0.200±0.068 | 0.198±0.110 |
| Heavy dose of | 5.37 | 0.186±0.116 | 0.192±0.075 | 0.216±0.087 | 0.191±0.071 | 0.152±0.059 |
| Middle dosage | 2.68 | 0.161±0.050 | 0.213±0.044 | 0.189±0.138 | 0.165±0.105 | 0.140±0.085 |
| Low dose of | 1.34 | 0.194±0.109 | 0.155±0.107 | 0.175±0.126 | 0.167±0.077 | 0.140±0.081 |
The result shows that with the comparison of ordinary water group, each administration group rabbit causes swollen afterwards 12h, 24h, 48h, the swelling of 72h knee joint at MSU all reduction trend, still not statistically significant.
The result shows that each dosage of granule of embodiment 2 preparations has reduction trend to gout model man rabbit knee swelling degree.
The influence of the pathological change of the tame rabbit knee Synovial membrane of table 16
| Group | Dosage/gkg -1 | Number of animals/only | 0 grade | The I level | The II level | The III level |
| The ordinary water group | Equal-volume | 6 | 0 | 0 | 1 | 5 |
| TONGFENGDING | 0.28 | 6 | 0 | 0 | 4 | 2 |
| Big agent | 5.37 | 6 | 0 | 2 | 4 | 0 ** |
| Middle dosage | 2.68 | 6 | 0 | 1 | 4 | 1 * |
| Low dose of | 1.34 | 6 | 0 | 0 | 4 | 2 |
Annotate: compare with the ordinary water group,
*P＜0.05,
*P＜0.01.
The result shows that the big or middle dosage group of granule and the ordinary water group of embodiment 2 preparations compare, and tame rabbit knee synovial membrane tissue pathological change diversity of values has significance meaning (P＜0.01, P＜0.01).
With reference to above-mentioned experimental program the Chinese medicine composition of embodiment 1, embodiment 3 preparations is tested, proved all have similar therapeutic effect.
Embodiment 13: Chinese medicine composition of the present invention is to the cytophagous influence of mouse monokaryon
Get 50 of KM mices, male and female half and half, body weight (20 ± 2) g, by the body weight random packet, grouping, administration be with embodiment 4, continuous 7 days.30min after the last administration, every caudal vein injection india ink 0.1mL10g
-12min, 20min get blood 20 μ L with quantitative capillary tube by the mouse orbit rear vein beard respectively at the injection back, be dissolved in 0.1% the sodium carbonate liquor and shake up, put ultraviolet-visible spectrophotometer 650nm place and survey the absorbance A value, put to death mice, take by weighing liver, spleen weight respectively, calculate carbon clearance index K and proofread and correct carbon clearance index α.
The results are shown in Table 17.
The granule of table 17 embodiment 3 preparation is to the cytophagous influence of mouse monokaryon (x ± s)
| Group | Dosage/gkg -1 | Number of animals | K value/* 10 -3 | The α value |
| Contrast | Equal-volume | 10 | 4.050±1.939 | 2.866±0.512 |
| TONGFENGDING | 0.8 | 10 | 5.980±3.137 | 3.232±0.547 |
| Heavy dose of | 15.40 | 10 | 9.726±4.792 ** | 3.863±0.537 *** |
| Middle dosage | 7.70 | 10 | 7.156±3.575 * | 3.420±0.419 ** |
| Low dose of | 3.85 | 10 | 6.338±4.049 | 3.259±0.592 |
Annotate: compare with the ordinary water group,
*P＜0.05,
*P＜0.01,
* *P＜0.001.
K=(logA
1-logA
2)/(t
2-t
1), α=K
-3* body weight/(liver weight+spleen is heavy)
The result shows that the big or middle dosage of granule of embodiment 3 preparations can significantly improve mice carbon clearance exponential sum and proofread and correct the carbon clearance index, to the effect of improving of mice nonspecific immunity.With reference to above-mentioned experimental program the Chinese medicine composition of embodiment 1, embodiment 2 preparations is tested, proved that all significantly improving mice carbon clearance exponential sum proofreaies and correct the carbon clearance index.
Embodiment 14: Chinese medicine composition of the present invention is to the influence of mice serum hemolysin
Get 50 of KM mices, male and female half and half, body weight (20 ± 2) g, grouping, administration with embodiment administration in 4, the 1 days after, each is organized mouse peritoneal and injects 5% normal saline chicken red blood cell suspension 0.2mL and carry out immunity, continues administration 6 days.Behind the last administration 1h, pluck eyeball and get blood, centrifugal, get serum and dilute 100 times with normal saline, get dilute serum 1mL, mix with 5% chicken erythrocyte suspension 0.5mL, 10% complement 0.5mL, in 37 ℃ of calorstats the insulation 30min after, stopped reaction in 0 ℃ of ice, centrifugal, get supernatant, in ultraviolet-visible spectrophotometer 540nm place colorimetric, survey absorbance.
The results are shown in Table 18.
The granule of table 18 embodiment 3 preparation is to the influence of mice hemolysin level (x ± s)
| Group | Dosage/gkg -1 | Number of animals/only | Absorbance | Average raising rate/% |
| Normal control | Equal-volume | 10 | 1.315±0.532 | - |
| TONGFENGDING | 0.8 | 10 | 1.523±0.472 | 15.8 |
| Heavy dose of | 15.40 | 10 | 1.873±0.351 * | 42.4 |
| Middle dosage | 7.70 | 10 | 1.797±0.403 * | 36.7 |
| Low dose of | 3.85 | 10 | 1.535±0.431 | 16.7 |
Annotate: compare with the ordinary water group,
*P＜0.05.
Average raising rate=(administration group mean light absorbency-ordinary water group mean light absorbency)/ordinary water group mean light absorbency * 100%
The result shows, the big or middle dosage group of granule and the ordinary water group comparison absorbance difference of embodiment 3 preparations have significance meaning (P＜0.05), show that the granule of embodiment 3 preparations can improve the level of mice serum hemolysin, to the mouse humoral immune effect of improving.With reference to above-mentioned experimental program the Chinese medicine composition of embodiment 1, embodiment 2 preparations is tested, proved the level that can improve the mice serum hemolysin.More than test shows that the present invention has gout effect preferably, is the good medicine for the treatment of gout.
Embodiment 15: Chinese medicine composition toxicologic study of the present invention
1. acute toxicity test: recording and irritating the stomach maximum dosage-feeding in the mice one day is 414.0g/kg (crude drug/body weight of embodiment 1 preparation), is equivalent to 537.7 times of people's clinical application amount, does not see the overt toxicity reaction.
2. long term toxicity test: Chinese medicine composition of the present invention is carried out the rat long term toxicity test.Experimental result shows that the safe dose that continuous 24 weeks of rat gavage is more than 7.7g/kg.
The present invention treats the compound medicine of gout, has advantage evident in efficacy, that flavour of a drug are few, purity is high, side effect is little.The preparation method of medicine of the present invention has extraction ratio height, purity height, simple to operate, is fit to suitability for industrialized production.
The present invention is not limited to above-mentioned preferred forms, and other any identical with the present invention or akin products that anyone draws under enlightenment of the present invention all drop within protection scope of the present invention.
Claims (9)
1. Chinese medicine composition for the treatment of gout, described raw material is by weight: Radix Puerariae 240～340 weight portions, Radix Salviae Miltiorrhizae 380～480 weight portions, Caulis Lonicerae 520～620 weight portions, Semen Coicis 420～520 weight portions, Semen Plantaginis 380～480 weight portions.
2. Chinese medicine composition according to claim 1 is characterized in that, described raw material is by weight: Radix Puerariae 286 weight portions, Radix Salviae Miltiorrhizae 429 weight portions, Caulis Lonicerae 571 weight portions, Semen Coicis 476 weight portions, Semen Plantaginis 429 weight portions.
3. Chinese medicine composition according to claim 1 and 2 is characterized in that, described Chinese medicine composition directly or indirectly adds acceptable accessories through conventional processing and makes granule, pill, powder, tablet, capsule, oral liquid.
4. Chinese medicine composition according to claim 3 is characterized in that, described adjuvant comprises dextrin and steviosin.
5. Chinese medicine composition according to claim 3, it is characterized in that, described steviosin weight accounts for 5 ‰ of Radix Puerariae, Radix Salviae Miltiorrhizae, Caulis Lonicerae, Semen Coicis and Semen Plantaginis total amount, and described dextrin weight is 1 ︰ 1.5～3 with the total amount ratio of Radix Puerariae, Radix Salviae Miltiorrhizae, Caulis Lonicerae, Semen Coicis, Semen Plantaginis.
6. the preparation method of each described Chinese medicine composition of claim 1-2 is characterized in that, may further comprise the steps:
Step a: Radix Salviae Miltiorrhizae extracts secondary with alcohol heating reflux, and merge extractive liquid, filters, and gets filtrate and is concentrated into 60 ℃～75 ℃ to survey relative densities be 1.20～1.22 clear paste, and is standby;
Step b: step a is filtered the gained medicinal residues decoct with water twice, merging filtrate, being concentrated into 60 ℃～75 ℃, to survey relative densities be 1.20～1.22 clear paste, standby;
Step c: Radix Puerariae, Caulis Lonicerae, Semen Coicis, Semen Plantaginis are added alcohol heating reflux extract secondary, merge extractive liquid, filters, and being concentrated into 60 ℃～75 ℃, to survey relative densities be 1.20～1.22 clear paste, standby;
Steps d: each step gained clear paste is merged, namely.
7. preparation method according to claim 6 is characterized in that, the described ethanol of step a is 80% ethanol, and its consumption that refluxes for the first time is 8-12 times of Radix Salviae Miltiorrhizae weight, and its consumption that refluxes for the second time is 6-10 times of Radix Salviae Miltiorrhizae weight.
8. preparation method according to claim 6 is characterized in that, twice decocting time of step b was respectively 2 hours, 1 hour.
9. preparation method according to claim 6, it is characterized in that, the described ethanol of step c is 50% ethanol, its consumption that refluxes for the first time is Radix Puerariae, Caulis Lonicerae, Semen Coicis, Semen Plantaginis gross weight 8 times, and its consumption that refluxes for the second time is Radix Puerariae, Caulis Lonicerae, Semen Coicis, Semen Plantaginis gross weight 6 times.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200910163143 CN101991792B (en) | 2009-08-18 | 2009-08-18 | Traditional Chinese medicinal composition for treating gout and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200910163143 CN101991792B (en) | 2009-08-18 | 2009-08-18 | Traditional Chinese medicinal composition for treating gout and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101991792A CN101991792A (en) | 2011-03-30 |
| CN101991792B true CN101991792B (en) | 2013-08-07 |
Family
ID=43782868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200910163143 Active CN101991792B (en) | 2009-08-18 | 2009-08-18 | Traditional Chinese medicinal composition for treating gout and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101991792B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103372159A (en) * | 2012-04-26 | 2013-10-30 | 浙江大学城市学院 | Semen-coicis extract with function of reducing blood uric acid and method for preparing same |
| CN103356808B (en) * | 2013-06-14 | 2016-03-09 | 张静 | A kind of Chinese medicine for the treatment of gout |
| CN103735927B (en) * | 2013-12-25 | 2016-03-30 | 柳州市中医院 | A kind of Chinese medicine composition for the treatment of acute stage of gout and preparation method thereof |
| CN106266763A (en) * | 2016-08-29 | 2017-01-04 | 王旭时 | One treats gout Chinese medicine preparation and preparation method thereof |
| CN107519270B (en) * | 2017-10-19 | 2018-05-22 | 林嗣松 | A kind of application of Chinese medicine and its extraction composition in gout is treated |
| CN111939235A (en) * | 2020-08-24 | 2020-11-17 | 柳州市中医医院 | Forming process method of compound gout granules |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100400082C (en) * | 2005-04-25 | 2008-07-09 | 南京中医药大学 | Pharmaceutical composition for treating acute gout and its extraction method |
-
2009
- 2009-08-18 CN CN 200910163143 patent/CN101991792B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100400082C (en) * | 2005-04-25 | 2008-07-09 | 南京中医药大学 | Pharmaceutical composition for treating acute gout and its extraction method |
Non-Patent Citations (2)
| Title |
|---|
| 唐丽.痛风的中医临床及实验研究近况.《中国中医急症》.2005,第14卷(第1期),第75-77页. |
| 痛风的中医临床及实验研究近况;唐丽;《中国中医急症》;20050131;第14卷(第1期);第75-77页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101991792A (en) | 2011-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101991792B (en) | Traditional Chinese medicinal composition for treating gout and preparation method thereof | |
| CN100531769C (en) | Chinese medicine composition for treating gout and preparing method thereof | |
| CN101496893B (en) | Chinese medicinal composition for treating gall stone symptom and preparation method thereof | |
| CN102205107B (en) | Chinese medicinal preparation for treating duodenal ulcer and preparation method thereof | |
| CN100443112C (en) | Medicine for treating gout and gout arthritis | |
| CN102205108B (en) | Traditional Chinese medicine preparation for treating gastric ulcer and preparation method thereof | |
| CN101920002B (en) | Chinese medicinal formula for treating gout and hyperuricemia | |
| CN105748543A (en) | Traditional Chinese medicine composition for treating rheumatic disease and preparing method of traditional Chinese medicine composition | |
| CN101085039B (en) | Composition for preventing and treating diabetes (hyperglycaemia) and its preparation method | |
| CN103877438A (en) | Traditional Chinese medicine preparation for treating gout and production method thereof | |
| CN100384462C (en) | Medicinal composition for treating acute urarthritis and its preparation method | |
| CN102579999A (en) | Medicine for treating carcinous fever and preparation method thereof | |
| CN100333758C (en) | Gout resisting Chinese medicine composition and its prepn process | |
| CN101234165B (en) | Pharmaceutical combination for treating asthma or rhinitis and preparation thereof | |
| KR100573245B1 (en) | Composition for relieving hangover and improving liver function | |
| CN102366540B (en) | Medicine for treating diabetes and its preparation method | |
| CN102488825B (en) | Traditional Chinese medicine composition for treating beriberoid pyretic arthralgia and application of traditional Chinese medicine composition | |
| CN102973696B (en) | Traditional Chinese medicine composition for treating chronic enteritis and preparation method of traditional Chinese medicine composition | |
| CN101623457B (en) | Traditional Chinese medicine for treating chronic prostatitis | |
| CN101554396A (en) | Traditional Chinese medicine for treating diabetes and hyperlipidemia | |
| CN103550335A (en) | Traditional Chinese medicinal composition for improving liver function | |
| CN102895543B (en) | Traditional Chinese medicine detoxifying decoction for treating uremia | |
| CN100409893C (en) | Medicine for treating functional renal failure and preparation method thereof | |
| CN106902295B (en) | Toxicity-reducing and efficacy-enhancing traditional Chinese medicine tablet for treating gout with syndrome of wind-damp-heat | |
| CN102139077B (en) | Medicament for treating gout and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: QINGDAO HAICHUAN CENTER FOR INNOVATIVE BIOMEDICAL Free format text: FORMER OWNER: ZHU HONGLONG Effective date: 20130222 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 266061 QINGDAO, SHANDONG PROVINCE TO: 266071 QINGDAO, SHANDONG PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20130222 Address after: Laoshan District of Shandong city of Qingdao province Hongkong 266071 Road No. 316 Nonghaiyuan B20 Applicant after: Qingdao Haichuan Center for Innovative Biomedical Research Address before: 266061 Shandong Province, Qingdao city Hongkong Road No. 316 Nonghaiyuan B20 Applicant before: Zhu Honglong |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: JILIN XIUZHENG PHARMACEUTICAL NEW MEDICINE DEVELOP Free format text: FORMER OWNER: QINGDAO HAICHUAN CENTER FOR INNOVATIVE BIOMEDICAL RESEARCH Effective date: 20131219 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 266071 QINGDAO, SHANDONG PROVINCE TO: 130012 CHANGCHUN, JILIN PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20131219 Address after: 130012 No. 2426 Qianjin Street, Changchun hi tech Development Zone, Jilin Patentee after: Jilin xiuzheng pharmaceutical new medicine development Co., Ltd. Address before: Laoshan District of Shandong city of Qingdao province Hongkong 266071 Road No. 316 Nonghaiyuan B20 Patentee before: Qingdao Haichuan Center for Innovative Biomedical Research |
|
| ASS | Succession or assignment of patent right |
Owner name: LIAONING XIUZHENG BIOLOGICAL PHARMACEUTICAL CO., L Effective date: 20140324 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20140324 Address after: 130012 No. 2426 Qianjin Street, Changchun hi tech Development Zone, Jilin Patentee after: Jilin xiuzheng pharmaceutical new medicine development Co., Ltd. Patentee after: Liaoning revised Biological Pharmaceutical Co Ltd Address before: 130012 No. 2426 Qianjin Street, Changchun hi tech Development Zone, Jilin Patentee before: Jilin xiuzheng pharmaceutical new medicine development Co., Ltd. |